With 1.2 million shares changed hands, the volume of the stock remained lighter than its average volume of 19.34 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.3394 whereas the lowest price it dropped to was $0.2901. The 52-week range on GLYC shows that it touched its highest point at $3.53 and its lowest point at $0.14 during that stretch. It currently has a 1-year price target of $0.50. Beta for the stock currently stands at 1.75.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GLYC was down-trending over the past week, with a drop of -15.33%, but this was up by 90.84% over a month. Three-month performance surged to 88.82% while six-month performance rose 25.15%. The stock lost -78.74% in the past year, while it has lost -86.40% so far this year.
Float and Shares Shorts:
At present, 64.39 million GLYC shares are outstanding with a float of 57.07 million shares on hand for trading. On 2024-10-31, short shares totaled 5.64 million, which was 874.0 higher than short shares on 1727654400. In addition to Mr. Harout Semerjian as the firm’s CEO, President & Director, Ms. Rachel K. King serves as its Co-Founder & Director.
Institutional Ownership:
Through their ownership of 0.47911 of GLYC’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, GLYC reported revenue of $0.0 and operating income of -$5721347.0. The EBITDA in the recently reported quarter was -$1425567.0 and diluted EPS was -$0.15.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GLYC since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GLYC analysts setting a high price target of 1.0 and a low target of 1.0, the average target price over the next 12 months is 1.0. Based on these targets, GLYC could surge 212.5% to reach the target high and rise by 212.5% to reach the target low. Reaching the average price target will result in a growth of 212.5% from current levels.
Analysts have provided yearly estimates in a range of -$0.51 being high and -$0.51 being low. For GLYC, this leads to a yearly average estimate of -$0.51.
